Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2010

View Archived Issues

Cediranib shows potential to treat epithelial ovarian, fallopian tube and peritoneal cancer

European Commission approves Pfizer's Revatio injection for pulmonary arterial hypertension

Ark Therapeutics files request with EMEA for re-examination of MAA for Cerepro

Boston Scientific initiates enrollment into postapproval study of Taxus Liberte stent

Data reported from three phase II studies of BIBW-2992 in metastatic breast cancer

PEG 15-20 to enter clinical trial after shown to protect rodent intestine from radiation

DAPH-12 and epigallocatechin gallate synergize to inhibit prion strains

8-Chloro-adenosine to be investigated in patients with breast cancer

BioInvent initiates treatment in phase I trial of BI-505 antibody for multiple myeloma

BioForm Medical to be acquired by Merz and renamed Merz Aesthetics

Dynavax Technologies acquires Symphony Dynamo

Dainippon Sumitomo submits NDA to FDA for lurasidone in schizophrenia

FDA grants priority review to InterMune's NDA for pirfenidone for idiopathic pulmonary fibrosis

Adventrx submits NDA to FDA for ANX-530

Anterogen begins phase I trial of ANT-SM in fecal incontinence

Novo Nordisk initiates phase I trial of oral insulin analogue NN-1952

First-in-man study of EMD-1214063 initiated in patients with solid tumors

FDA approves Takeda's sNDA for Velcade for first-line treatment of multiple myeloma

Janssen discloses novel HDAC inhibitors for cancer treatment

Swiss scientists present novel BB2 antagonists for cancer diagnosis and treatment

Dr. Reddy's Laboratories and Nordic Bioscience report results from phase III balaglitazone trial

MethylGene describes tyrosine kinase inhibitors for the treatment of proliferative diseases

Janssen presents protein kinase inhibitors for cancer therapy

Chinese scientists describe novel compounds for cancer treatment

NeoPharm files IND with FDA for phase I trial of IL-13-PE38QQR in idiopathic pulmonary fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...